Odyssey Therapeutics ODTX
$16.96 −$1.38 (-7.52%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $16.96 0.00%
Open$17.65
Prev close$18.34
Day range$16.46 – $18.08
Volume677.8K
Market cap$815.23M
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00-100.0% YoY
Operating profit-$53.36M-46.7% YoY
Net profit-$53.06M-49.6% YoY
Diluted EPS-$1.10-46.3% YoY
Free cash flow-$42.05M-34.3% YoY
Operating cash flow-$41.54M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Return on equity-47.3%
Return on assets-40.5%
Return on invested capital-47.1%
Current ratio12.94
Liabilities / assets14.2%
Cash & investments$326.00M
Total debt$17.95M
Net cash (debt)$308.06M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $0.00 | $0.00 | $0.00 | $2.98M | $0.00 |
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $2.98M | $0.00 |
| Operating Expense | $53.36M | $46.74M | $39.67M | $164.13M | $37.48M |
| Selling and Admin Expenses | $11.24M | $10.51M | $7.35M | $37.52M | $6.19M |
| -General & Admin Expense | $11.24M | $10.51M | $7.35M | $37.52M | $6.19M |
| Research & Development | $42.12M | $36.23M | $32.32M | $126.62M | $31.29M |
| Operating Profit | -$53.36M | -$46.74M | -$39.67M | -$161.16M | -$37.48M |
| Net Non-Operating Interest Income (Expense) | $3.85M | $2.81M | $1.70M | $6.33M | $2.11M |
| Non-Operating Interest Income | $3.86M | $2.83M | $1.71M | $6.35M | $2.12M |
| Non-Operating Interest Expense | $12,000.00 | $20,000.00 | $10,000.00 | $17,000.00 | $12,000.00 |
| Other Income (Expense) | -$3.50M | -$8.87M | -$226,000.00 | $5.25M | $813,000.00 |
| Special Income (Charges) | -$3.31M | -$8.73M | -$109,000.00 | $4.05M | -$295,000.00 |
| -Less:Restructuring and Mergern & Acquisition | $3.31M | $8.73M | $109,000.00 | -$4.05M | $295,000.00 |
| Other Non-Operating Income (Expenses) | -$194,000.00 | -$138,000.00 | -$117,000.00 | $1.20M | $1.11M |
| Pretax Profit | -$53.01M | -$52.80M | -$38.20M | -$149.57M | -$34.56M |
| Tax | $49,000.00 | -$8,000.00 | $63,000.00 | -$927,000.00 | -$1.04M |
| Net Profit | -$53.06M | -$52.79M | -$38.26M | -$148.65M | -$33.52M |
| Profit from Continuing Operations | -$53.06M | -$52.79M | -$38.26M | -$148.65M | -$33.52M |
| Net Income to Parent Company | -$53.06M | -$52.79M | -$38.26M | -$148.65M | -$33.52M |
| Net Income to Common Stockholders | -$53.06M | -$52.79M | -$38.26M | -$148.65M | -$33.52M |
| Basic EPS | -$1.10 | -$1.74 | -$0.81 | -$5.39 | -$0.71 |
| Diluted EPS | -$1.10 | -$1.74 | -$0.81 | -$5.39 | -$0.71 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $438.10M | $483.85M | $229.07M | $269.79M | $269.79M |
| Total Current Assets | $337.80M | $321.46M | $185.10M | $190.66M | $190.66M |
| Cash and Cash Equivalents & Short-Term Investments | $326.00M | $310.58M | $175.75M | $181.36M | $181.36M |
| -Cash and Cash Equivalents | $80.64M | $82.03M | $35.72M | $41.69M | $41.69M |
| -Short Term Investments | $245.36M | $228.54M | $140.03M | $139.67M | $139.67M |
| Other Current Assets | $11.80M | $10.89M | $9.35M | $9.30M | $9.30M |
| Total Non-Current Assets | $100.30M | $162.39M | $43.97M | $79.13M | $79.13M |
| Net PPE | $20.76M | $21.92M | $24.48M | $26.01M | $26.01M |
| -Gross PPE | $34.63M | $34.95M | $39.58M | $40.17M | $40.17M |
| -Accumulated Depreciation | -$13.86M | -$13.04M | -$15.11M | -$14.16M | -$14.16M |
| Investments and Advances | $60.99M | $122.49M | $0.00 | $35.20M | $35.20M |
| -Available for Sale Securities | $60.99M | $122.49M | – | $35.20M | $35.20M |
| Goodwill and Other Intangible Assets | $14.12M | $14.19M | $14.23M | $14.59M | $14.59M |
| -Goodwill | $14.12M | $14.10M | $14.07M | $14.33M | $14.33M |
| Other Non-Current Assets | $4.43M | $3.79M | $5.26M | $3.33M | $3.33M |
| Total Liabilities | $62.33M | $62.63M | $752.76M | $758.07M | $758.07M |
| Total Current Liabilities | $26.10M | $28.30M | $22.21M | $26.48M | $26.48M |
| Payables | $8.26M | $7.67M | $8.22M | $7.87M | $7.87M |
| -Accounts Payable | $8.26M | $7.67M | $8.22M | $7.87M | $7.87M |
| Current Accrued Expenses | $6.53M | $8.16M | $4.42M | $6.25M | $6.25M |
| Short-Term Debt and Capital Lease Obligation | $5.53M | $5.47M | $5.37M | $5.21M | $5.21M |
| -Current Capital Lease Obligation | $5.53M | $5.47M | $5.37M | $5.21M | $5.21M |
| Current Deferred Liabilities | $20,000.00 | $3.17M | $1.45M | $64,000.00 | $64,000.00 |
| Other Current Liabilities | $839,000.00 | $492,000.00 | $399,000.00 | $374,000.00 | $374,000.00 |
| Total Non-Current Liabilities | $36.23M | $34.33M | $730.55M | $731.59M | $731.59M |
| Long Term Debt and Capital Lease Obligation | $17.95M | $19.36M | $20.75M | $21.90M | $21.90M |
| -Long Term Capital Lease Obligation | $17.95M | $19.36M | $20.75M | $21.90M | $21.90M |
| Convertible preferred securities | $0.00 | $0.00 | $703.56M | $703.56M | $703.56M |
| Other Non-Current Liabilities | $18.28M | $14.97M | $6.24M | $6.13M | $6.13M |
| Total Equity | $375.77M | $421.22M | -$523.69M | -$488.28M | -$488.28M |
| Stockholders' Equity | $375.77M | $421.22M | -$523.69M | -$488.28M | -$488.28M |
| Capital Stock | $5,000.00 | $5,000.00 | $0.00 | $0.00 | $0.00 |
| -Common Stock | $5,000.00 | $5,000.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $1.09B | $1.08B | $82.85M | $79.62M | $79.62M |
| Retained Earnings | -$712.25M | -$659.19M | -$606.40M | -$568.14M | -$568.14M |
| Gains/Losses Not Affecting Retained Earnings | -$985,000.00 | -$505,000.00 | -$147,000.00 | $245,000.00 | $245,000.00 |
| -Other Intangible Assets | – | $86,000.00 | $160,000.00 | $262,000.00 | $262,000.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$41.54M | -$34.51M | -$41.04M | -$129.47M | -$25.33M |
| Net cash flow from continuing operations | -$41.54M | -$34.51M | -$41.04M | -$129.47M | -$25.33M |
| Net Income from Continuing Operations | -$53.06M | -$52.79M | -$38.26M | -$148.65M | -$33.52M |
| Gain/Loss from Continuing Operations | -$4,000.00 | $639,000.00 | -$33,000.00 | $1.36M | $201,000.00 |
| Depreciation & Depletion & Amortization | $1.01M | $1.04M | $1.17M | $4.91M | $1.16M |
| Other Non-Cash Items | $4.21M | $9.68M | $988,000.00 | -$606,000.00 | $1.43M |
| Change in Working Capital | -$1.98M | $1.17M | -$7.19M | -$4.73M | $3.31M |
| -Change in Prepaid Assets | -$907,000.00 | -$1.59M | $3,000.00 | -$3.21M | -$2.08M |
| -Change in Payables and Accrued Expense | $865,000.00 | $2.55M | -$4.28M | -$2.09M | $6.87M |
| -Change in Other Current Assets | -$637,000.00 | $1.47M | -$1.69M | $5.16M | $105,000.00 |
| -Change in Other Current Liabilities | -$1.30M | -$1.26M | -$1.23M | -$4.60M | -$1.58M |
| Net cash flow from investing | $43.29M | -$211.44M | $34.80M | -$103.94M | $11.53M |
| Net Cash Flow from Continuing Investing Activities | $43.29M | -$211.44M | $34.80M | -$103.94M | $11.53M |
| Net PPE Purchase and Sale | -$483,000.00 | $95,000.00 | -$148,000.00 | -$875,000.00 | -$228,000.00 |
| Net Investment Purchase and Sale | $43.78M | -$211.54M | $34.95M | -$103.07M | $11.75M |
| Financing Cash Flow | -$3.18M | $292.16M | $484,000.00 | $215.65M | $5.94M |
| Net Cash Flow from Continuing Financing Activities | -$3.18M | $292.16M | $484,000.00 | $215.65M | $5.94M |
| Net Issuance Payments Of Debt | -$47,000.00 | -$46,000.00 | -$24,000.00 | – | – |
| Net Common Stock Issuance | -$3.28M | – | – | – | – |
| Net Preferred Stock Issuance | $0.00 | – | – | $212.46M | $2.98M |
| Proceeds from Stock Option Exercised | $152,000.00 | $586,000.00 | $651,000.00 | $3.19M | $2.86M |
| Ending Cash Balance | $84.09M | $85.48M | $39.17M | $44.90M | $44.90M |
| Net Change in Cash | -$1.43M | $46.21M | -$5.75M | -$17.77M | -$7.86M |
| Beginning Cash Balance | $85.48M | $39.17M | $44.90M | $62.35M | $52.73M |
| Effect of Exchange Rate Changes | $38,000.00 | $104,000.00 | $24,000.00 | $316,000.00 | $25,000.00 |
| Free Cash Flow | -$42.05M | -$34.69M | -$41.18M | -$130.70M | -$25.56M |
| Net Other Financing Charges | – | – | -$143,000.00 | – | – |
No comments yet — be the first to weigh in on ODTX.
Sign in to join the discussion.